HAE

Haemonetics Corporation develops, manufactures, and markets automated blood processing systems and medical devices for blood and plasma collection, processing, and management. Headquartered in Boston, Massachusetts, the company operates through three primary segments: Plasma, Blood Center, and Hospital. Haemonetics serves blood and plasma collectors, hospitals, and military organizations across more than 100 countries worldwide. The company's Plasma segment provides automated plasma collection devices and disposables to plasma collectors, while its Blood Center division offers automated blood component collection and processing systems. The Hospital segment delivers hemostasis management solutions, blood salvage systems, and surgical sealants used in cardiac and orthopedic procedures. Key products include the NexSys PCS plasma collection system, TEG hemostasis analyzers, and Cell Saver blood salvage technology. Haemonetics employs approximately 3,800 people globally and operates manufacturing facilities in the United States, Europe, and Asia. The company generated approximately $1.1 billion in revenue in fiscal 2023. In recent years, Haemonetics has focused on digital health initiatives and expanded its plasma business through capacity increases and technological innovations. The company has also pursued strategic acquisitions to strengthen its hospital portfolio, including the purchase of OpSens' surgical product line in 2023, enhancing its cardiac surgery offerings. Haemonetics maintains a significant market position in plasma collection and blood management technologies.